CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-09). The draft was written by AI, all 5 cited sources were opened and checked for existence, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 170 · Search date 2026-07-09 · Methodology v0.6

Lycopene,
does it really help with Cardiovascular, prostate?

30-Second Summary
C
Evidence Grade C · 43 · Safety acceptable
There are laboratory-value signals, but they are not evidence for preventing prostate cancer or cardiovascular events.
What the
research shows
There are human studies of tomato foods and lycopene supplements that examined markers such as lipids, blood pressure, endothelial function, and PSA, but the results are mixed and mostly involve surrogate markers. For cardiovascular outcomes, null results in healthy people and endothelial-function signals in CVD patients are mixed; for prostate cancer, the evidence is only observational and food-intake signals, so it is not approved evidence for cancer treatment or prevention.
What the
ads claim
Advertising mentions 'prostate health,' 'men's health,' 'antioxidant,' 'vascular health,' and 'LDL oxidation inhibition.' The actual evidence is mainly surrogate markers such as blood values, vascular function, and PSA.
*

Useful facts when choosing a product

  • Tomato foods, tomato extracts, and synthetic lycopene capsules differ in accompanying components and absorption.
  • Because it is fat-soluble, absorption can vary when taken with fat.
  • Clinical benefit from long-term high-dose intake is not established, and yellow skin discoloration (lycopenemia) can be reported.
  • Adjunctive use in people being treated for prostate cancer should be judged separately with clinicians.
  • Anticancer or cancer-prevention claims are considered separately from the cardiovascular surrogate-marker C verdict and are viewed as insufficiently supported (D/unknown).
Gap Measurement · Verdict 170 · C 43
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

A 2017 Atherosclerosis meta-analysis reported that tomato/lycopene supplementation improved some blood lipid and blood-pressure markers. A 2020 Advances in Nutrition RCT review concluded that evidence on cardiovascular risk factors was conflicting. A 2014 PLoS ONE RCT showed a signal of improved endothelial function in patients with cardiovascular disease, but it was not clear in healthy people. On the prostate side, evidence centers on dietary-intake observational studies and PSA/tissue biomarker studies, and the FDA and NCI do not approve or recognize lycopene as effective for cancer treatment or prevention.

02

Why this is classified as C (43)

Because human studies exist, this is not unknown or D, but the core evidence is surrogate markers and conflicting findings. Cardiovascular evidence centers on lipid, blood-pressure, and endothelial-function surrogate markers and mixes null results in healthy people with endothelial signals in CVD patients. Prostate cancer remains at the level of observational/food-intake signals, so anticancer/cancer-prevention efficacy is separated lower at D/unknown; overall this is lower-end C, 43 points.

Counterpoint. Diet studies including tomato foods and studies of lycopene as a single supplement should be considered together but not treated as identical.

Rejudgment record. Final — Cardiovascular evidence centers on lipid, blood-pressure, and endothelial-function surrogate markers, while prostate-cancer evidence consists of observational/food-intake signals and non-approval by regulators, so anticancer/cancer-prevention claims are separately insufficiently supported

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Cheng HM et al. 2017Systematic review and meta-analysisAcademic/unknownRisk factors such as blood lipids and blood pressureReported improvements in some lipid and blood-pressure markers.Core
Tierney A et al. 2020Systematic review and meta-analysisAcademic/unknownCardiovascular risk factorsConcluded that lycopene effects on cardiovascular risk factors were conflicting.Core
Gajendragadkar PR et al. 2014Randomized placebo-controlled trial36Unknown/academicEndothelial functionEndothelial function improved in patients with cardiovascular disease, but not clearly in healthy people.Supporting
§

Receipt — 5 References

Every cited source was opened and checked against the live page on 2026-07-09.

Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. Tomato and lycopene supplementation and cardiovascular risk factors: a systematic review and meta-analysis. Atherosclerosis. 2017;257:100-108. DOI: 10.1016/j.atherosclerosis.2017.01.009.
checked
Tierney A, Rumble C, Billings L, George E. Effect of dietary and supplemental lycopene on cardiovascular risk factors: a systematic review and meta-analysis. Adv Nutr. 2020;11(6):1453-1488. DOI: 10.1093/advances/nmaa069.
checked
Gajendragadkar PR, Hubsch A, Maki-Petaja KM, et al. Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. PLoS One. 2014;9(6):e99070. DOI: 10.1371/journal.pone.0099070.
checked
US Food and Drug Administration. Qualified Health Claims: Letter Regarding Tomatoes and Prostate Cancer (Lycopene Health Claim Coalition), updated 2015.
checked
National Cancer Institute. Lycopene. PDQ Cancer Information Summaries. Updated 2024.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-09 · Corrections: none

Cite this verdict

Lycopene × cardiovascular, prostate Evidence Grade C card
[Chamgap] Lycopene × cardiovascular, prostate — Evidence Grade C·43. 5 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/heart/lycopene-cardiovascular-prostate/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.